eTheRNA raises EUR 34 million in Series B financing to accelerate multiple mRNA therapeutic development programs through toclinical proof of concept

eTheRNA raises EUR 34 million…

Fund+ Announces Investment in Ona Therapeutics EUR30 Million Series A financing

Fund+ Announces Investment in Ona…

Immunic, Inc. Announces First Patients Dosed in its Phase 2, CALVID-1 Clinical Trial of IMU-838 in COVID-19

Immunic, Inc. Announces First Patients…

Notable Board Changes

Notable Board Changes Fund+ Appoints…

Confo Therapeutics Expands Board with Appointment of Rob Scott as Independent Director

Confo Therapeutics Expands Board with…

Immunic, Inc. Announces Pricing of $25 Million Public Offering of Common Stock

Immunic, Inc. Announces Pricing of…

Novadip Biosciences to unveil its 3M3 Platform at BIO Digital 2020

Novadip Biosciences to unveil its…

Confo Therapeutics Appoints Paolo Vicini as Chief Development Officer

Confo Therapeutics Appoints Paolo Vicini…

HORAMA appoints life sciences veteran Benedikt Timmerman as new Chairman

HORAMA appoints life sciences veteran…

Immunic, Inc. Receives First Regulatory Approval from German Health Authority BfArM to Initiate a Phase 2 Clinical Trial of its Selective Oral DHODH Inhibitor, IMU-838, in COVID-19 Patients

Immunic, Inc. Receives First Regulatory…